Free Trial

Abbott Laboratories (ABT) Stock Forecast & Price Target

Abbott Laboratories logo
$88.34 -2.28 (-2.52%)
Closing price 06/17/2026 03:59 PM Eastern
Extended Trading
$88.95 +0.61 (+0.69%)
As of 06/17/2026 08:00 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Abbott Laboratories - Analysts' Recommendations and Stock Price Forecast (2026)

Consensus Rating

Sell
1
Hold
4
Buy
21

Based on 26 Wall Street analysts who have issued ratings for Abbott Laboratories in the last 12 months, the stock has a consensus rating of "Moderate Buy." Out of the 26 analysts, 1 has given a sell rating, 4 have given a hold rating, 19 have given a buy rating, and 2 have given a strong buy rating for ABT.

Consensus Price Target

$118.30
33.92% Upside
According to the 26 analysts' twelve-month price targets for Abbott Laboratories, the average price target is $118.30. The highest price target for ABT is $143.00, while the lowest price target for ABT is $92.00. The average price target represents a forecasted upside of 33.92% from the current price of $88.34.
MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
Get the Latest News and Ratings for ABT and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for Abbott Laboratories and its competitors.

Sign Up
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

ABT Analyst Ratings Over Time

TypeCurrent Forecast
6/18/25 to 6/18/26
1 Month Ago
5/19/25 to 5/19/26
3 Months Ago
3/20/25 to 3/20/26
1 Year Ago
6/18/24 to 6/18/25
Strong Buy
2 Strong Buy rating(s)
2 Strong Buy rating(s)
2 Strong Buy rating(s)
1 Strong Buy rating(s)
Buy
19 Buy rating(s)
19 Buy rating(s)
15 Buy rating(s)
13 Buy rating(s)
Hold
4 Hold rating(s)
5 Hold rating(s)
4 Hold rating(s)
5 Hold rating(s)
Sell
1 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
Consensus Price Target$118.30$119.43$136.16$143.29
Forecasted Upside33.92% Upside34.48% Upside28.96% Upside8.27% Upside
Consensus RatingModerate BuyModerate BuyModerate BuyModerate Buy

ABT Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

ABT Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

Abbott Laboratories Stock vs. The Competition

TypeAbbott LaboratoriesMedical CompaniesBroader Market
Consensus Rating Score
2.85
2.29
2.52
Consensus RatingModerate BuyHoldModerate Buy
Predicted Upside33.92% Upside715.75% Upside16.18% Upside
News Sentiment Rating
Positive News

See Recent ABT News
Positive News
Positive News
DateBrokerageAnalystActionRatingPrice TargetReport Date
Upside/Downside
Details
6/16/2026
Weiss Ratings logo
Weiss Ratings
5 of 5 stars
 DowngradeHold (C-)Sell (D+)
6/12/2026
Bank of America Corporation logo
Bank of America
4 of 5 stars
 Lower Target$120.00 ➝ $102.00+14.47%
5/27/2026
David Roman
David Roman
Not Rated
Lower TargetBuy$121.00 ➝ $113.00+30.87%
4/27/2026Reiterated RatingBuy$131.00+43.71%
4/22/2026 DowngradeOutperformNeutral$92.00-0.89%
4/21/2026 Lower TargetBuy$140.00 ➝ $125.00+30.13%
4/21/2026 Lower TargetMarket Perform$119.00 ➝ $106.00+10.35%
4/20/2026 Lower TargetBuy$158.00 ➝ $135.00+40.54%
4/20/2026Lower TargetOverweight$144.00 ➝ $143.00+47.59%
4/17/2026Lower TargetOutperform$135.00 ➝ $130.00+36.73%
4/17/2026 Lower TargetOutperform$125.00 ➝ $110.00+15.70%
4/17/2026 Lower TargetOutperform$134.00 ➝ $120.00+26.22%
4/17/2026 Lower TargetOutperform$130.00 ➝ $115.00+20.96%
4/17/2026 Lower TargetNeutral$125.00 ➝ $115.00+20.96%
4/17/2026 Lower TargetOverweight$122.00 ➝ $109.00+14.65%
4/17/2026 Lower TargetOverweight$123.00 ➝ $110.00+15.70%
4/17/2026Lower TargetOverweight$135.00 ➝ $115.00+20.96%
4/17/2026 Lower TargetBuy$145.00 ➝ $135.00+41.99%
4/17/2026 Lower TargetBuy$136.00 ➝ $108.00+13.59%
4/17/2026 Lower TargetBuy$137.00 ➝ $115.00+20.96%
4/17/2026Lower TargetOutperform$132.00 ➝ $115.00+20.96%
4/17/2026Lower TargetBuy$145.00 ➝ $120.00+26.22%
4/17/2026Lower TargetBuy$145.00 ➝ $120.00+26.22%
1/29/2026 UpgradeHoldStrong-Buy
11/20/2025 UpgradeStrong-Buy
7/15/2025Boost TargetEqual Weight$127.00 ➝ $137.00+3.75%
7/30/2024 DowngradeBuyHold

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Thursday at 01:18 AM ET.


Should I Buy Abbott Laboratories Stock? ABT Pros and Cons Explained

These pros and cons were generated based on recent news and financial data from MarketBeat in order to provide readers with the fastest and most accurate insights. They were last updated on Thursday, June 11, 2026. Please send any questions or comments about these Abbott Laboratories pros and cons to contact@marketbeat.com.

Abbott Laboratories
Bull Case

green Wall Street bull icon

Here are some ways that investors could benefit from investing in Abbott Laboratories:

  • The current stock price is around $92.80, which may present a buying opportunity for investors looking for growth in the healthcare sector.
  • Abbott Laboratories reported a strong quarterly earnings performance, with earnings per share of $1.15, exceeding analysts' expectations, indicating robust financial health.
  • The company has a solid market capitalization of approximately $158.85 billion, reflecting its significant presence and stability in the healthcare market.
  • With a return on equity of 17.62%, Abbott Laboratories demonstrates effective management and profitability, which can be attractive to investors seeking reliable returns.
  • The firm has shown a year-over-year revenue increase of 7.8%, suggesting strong demand for its products and potential for continued growth.

Abbott Laboratories
Bear Case

red Wall Street bear icon

Investors should be bearish about investing in Abbott Laboratories for these reasons:

  • The stock has a relatively high P/E ratio of 25.55, which may indicate that it is overvalued compared to its earnings, potentially leading to a price correction.
  • Abbott Laboratories has a beta of 0.63, suggesting lower volatility compared to the market, which may limit potential high returns for aggressive investors.
  • The company’s two-hundred day moving average is significantly higher at $109.16, indicating that the stock may be underperforming relative to its historical performance.
  • Despite recent revenue growth, the healthcare sector can be subject to regulatory changes and market competition, which may impact future profitability.
  • The debt-to-equity ratio of 0.56, while manageable, indicates that the company does carry some debt, which could pose risks in a rising interest rate environment.

ABT Forecast - Frequently Asked Questions

According to the research reports of 26 Wall Street equities research analysts, the average twelve-month stock price forecast for Abbott Laboratories is $118.30, with a high forecast of $143.00 and a low forecast of $92.00.

26 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Abbott Laboratories in the last twelve months. There is currently 1 sell rating, 4 hold ratings, 19 buy ratings and 2 strong buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" ABT shares.

According to analysts, Abbott Laboratories's stock has a predicted upside of 33.92% based on their 12-month stock forecasts.

Over the previous 90 days, Abbott Laboratories's stock had 3 downgrades by analysts.

Analysts like Abbott Laboratories more than other "medical" companies. The consensus rating for Abbott Laboratories is Moderate Buy while the average consensus rating for "medical" companies is Hold. Learn more on how ABT compares to other companies.


This page (NYSE:ABT) was last updated on 6/18/2026 by MarketBeat.com Staff.
From Our Partners